Abstract: A method of preparing an antibody therapeutic is provided comprising: (a) providing a dissociated cell sample from at least one solid tumor sample obtained from a patient; (b) loading the dissociated cell sample into a microfluidic device having a flow region and at least one isolation region fluidically connected to the flow region; (c) moving at least one B cell from the dissociated cell sample into at least one isolation region in the microfluidic device, thereby obtaining at least one isolated B cell; and (d) using the microfluidic device to identify at least one B cell that produces antibodies capable of binding to cancer cells. The cancer cells can be the patient's own cancer cells. Also provided are methods of treating patients, methods of labeling or detecting cancer, engineered T or NK cells comprising antibodies or fragments thereof, and engineered antibody constructs.

Abstract: Disclosed is a computer implemented method and apparatus for making ownership changes to a storage subsystem. The host sends the first ownership change command to the storage subsystem then determines whether the storage subsystem responded with an error message. Upon responding to a determination that the storage subsystem responded with the error message, the host determines whether the storage subsystem indicated an error associated with an ownership change. In response to a determination that the storage subsystem indicated an error associated with an ownership change, the host sends a discover ownership message to the storage subsystem. Upon receiving a list of logical unit number associations from the storage subsystem, the host responds to receiving a list of logical unit number associations. The host performs a second ownership command to determine whether the list of logical unit number associations matches an ownership defined in the ownership change command.

Abstract: Effective stimulation of immune responses is achieved through the use of a group A streptococcal antigen combined with proteosome adjuvant. The compositions are provided in particular for intranasal administration. The vaccine compositions are provided for use in inducing an immune response in an individual for the treatment or prophylaxis of group A streptococcal infection in an individual, preferably via prevention or reduction of colonisation of the throat following intranasal administration.

Abstract: Effective stimulation of immune responses is achieved through the use of a group A streptococcal antigen combined with proteosome adjuvant. The compositions are provided in particular for intranasal administration. The vaccine compositions are provided for use in inducing an immune response in an individual for the treatment or prophylaxis of group A streptococcal infection in an individual, preferably via prevention or reduction of colonisation of the throat following intranasal administration.